News & Updates

Linnaeus Therapeutics Announces Presentation of Positive Phase 1 Clinical Data of LNS8801 at 2021 ASCO Annual Meeting

06/17/2021

Excerpt from the Press Release: HADDONFIELD, N.J., June 7, 2021 /PRNewswire/ — Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of clinical data from its phase 1 dose-escalation study of LNS8801 as a monotherapy and in combination with pembrolizumab at the…

Read More

Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors

06/17/2021

Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced data from the gastrointestinal (GI) mid-gut neuroendocrine tumors (NETs) cohort of its Phase 2 clinical trial of PEN-221, presented…

Read More

Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

06/16/2021

Excerpt from the Press Release: WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced positive preliminary topline results from its first in human Phase 2a, multicenter, randomized, double-blind, vehicle-controlled, parallel-group clinical trial to evaluate the efficacy,…

Read More

Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

06/16/2021

Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced two e-poster presentations at the 2021 ASCO Annual Meeting. The presentations include intra-patient dose escalation (IPDE) data from the INVICTUS Phase 3 study of QINLOCK in…

Read More

Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19

06/15/2021

Excerpt from the Press Release: SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the National Institutes of Health (NIH) has identified its experimental drug, Tempol, as a potentially potent antiviral for COVID-19. According to a study of cell cultures conducted by NIH researchers, Tempol demonstrated an ability to limit SARS-CoV-2 infection by impairing the activity…

Read More

Magenta Therapeutics Announces Additional Preliminary Positive Results From Ongoing Phase 2 Clinical Trial Of Mgta-145 And Plerixafor In Patients With Multiple Myeloma At The American Society Of Clinical Oncology (asco) Annual Meeting

06/15/2021

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 4, 2021– Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced additional positive results from a Phase 2 clinical trial of MGTA-145 and plerixafor in patients with multiple myeloma at the American Society…

Read More

Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision To Bring “Off-The-Shelf” NK Cell-Based Cancer Treatments Rapidly To Patients

06/14/2021

Excerpt from the Press Release: SAN DIEGO and STOCKHOLM, June 4th, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, Karolinska Institutet (“KI”) in Stockholm, Sweden, aimed at producing novel cell-based therapeutics using natural killer (“NK”) cells derived from…

Read More

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients

06/14/2021

Excerpt from the Press Release: CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced additional details pertaining to Cullinan Pearl’s ongoing Phase 1/2a trial of CLN-081 in Non-Small Cell Lung Cancer (NSCLC) patients whose tumors harbor epidermal…

Read More

C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation

06/13/2021

Excerpt from the Press Release: WATERTOWN, Mass., June 07, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today presented new pre-clinical data on CFT8919, a novel mutant-selective degrader of epidermal growth factor receptor (EGFR) in non-small…

Read More

Shattering cancer with quantum machine learning: A preview

06/12/2021

Excerpt from the Article by Joe Geraci, Founder of Netramark. Machine learning has become a standard tool for medical researchers attempting to model disease in various ways, including building models to predict response to medications, classifying disease subtypes, and discovering new therapies. In this preview, we review a paper that utilizes quantum computation in order…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives